Is HCTZ a Thiazide-Like Diuretic?
No, hydrochlorothiazide (HCTZ) is technically classified as a thiazide-type diuretic, not a thiazide-like diuretic, though the 2025 AHA/ACC guideline now groups them together under one umbrella term for simplicity. 1
Chemical Classification
The traditional distinction is based on chemical structure:
- HCTZ is a thiazide-type diuretic because it possesses a benzothiadiazine ring structure 1, 2
- Chlorthalidone and indapamide are thiazide-like diuretics because they lack this benzothiadiazine ring, though they remain closely related sulfonamide derivatives 1, 2
Current Guideline Terminology
The 2025 AHA/ACC guideline deliberately uses "thiazide-type diuretic" as a collective term for HCTZ, chlorthalidone, and indapamide to minimize confusion, acknowledging that the interchangeability debate continues 1. The guideline states that "in most settings, it is acceptable for clinicians to choose among these agents for treatment" 1.
Critical Distinction for Your 74-Year-Old Post-TIA Patient
For a patient with prior stroke/TIA, chlorthalidone or indapamide (the true thiazide-like agents) should be strongly preferred over HCTZ. 3
Here's why this matters:
Evidence in Secondary Prevention
The 2024 Diuretic Comparison Project secondary analysis found that among patients with prior MI or stroke, chlorthalidone reduced the composite outcome (stroke, MI, urgent revascularization, acute heart failure hospitalization, or noncancer death) by 27% compared to HCTZ (14.3% vs 19.4%; HR 0.73,95% CI 0.57-0.94; P=0.01) 3. Importantly, in this high-risk subgroup, there was no difference in hypokalemia rates between chlorthalidone and HCTZ 3.
Pharmacologic Differences
The thiazide-like agents have:
- Longer duration of action (48-72 hours for chlorthalidone vs shorter for HCTZ) 2, 4
- Greater potency in blood pressure reduction, particularly for 24-hour and nighttime BP control 5, 4, 6
- Superior efficacy in resistant hypertension, which is why the 2025 guideline specifically recommends thiazide-like diuretics in that setting 1
Common Pitfall to Avoid
Do not assume HCTZ and chlorthalidone are interchangeable simply because guidelines group them together terminologically. The 2025 guideline explicitly recognizes "differences in potency and half-life between these agents that may be relevant in some situations" 1, and your post-TIA patient represents exactly such a situation where these differences translate into meaningful clinical outcomes.
Practical Recommendation
Switch your 74-year-old post-TIA patient from HCTZ to chlorthalidone 12.5-25 mg daily (or indapamide 1.25-2.5 mg daily) to optimize secondary stroke prevention 5, 3. The equivalent dose conversion is approximately 2:1 (25 mg HCTZ = 12.5 mg chlorthalidone) 3.